| You are here: Home: BCU 3|2002: William Gradishar, MD: Select publications
select publications
endocrine therapy for premenopausal women
Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996;348:1189-1196. Abstract
Aebi S et al. Is chemotherapy alone adequate for young women with oestrogenreceptor- positive breast cancer? Lancet 2000;355(9218):1869-74. Abstract
Baum M et al. Management of premenopausal women with early breast cancer: Is there a role for goserelin? Proc ASCO 2001;Abstract 103.
Boccardo F et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718-27. Abstract
Celio L et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 1999;19:2261-8. Abstract
Cheung KL et al. The combined use of goserelin and anastrozole as second line endocrine therapy in premenopausal women with advanced breast cancer - A study of its clinical and endocrine effects. Proc ASCO 2001;Abstract 1937.
Davidson, N et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101). Proc ASCO 1999;Abstract 249A, 67A.
Dees EC, Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol 2001;28(4):322-31. Abstract
de Haes H et al. Early benefits in quality of life (QoL) observed in Zoladextreated versus CMF-treated pre-/perimenopausal patients with nodepositive early breast cancer. Proc ASCO 2001;Abstract 138.
Forward D et al. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000;Abstract 582.
Hoffken K, Kath R. The role of LH-RH analogues in the adjuvant and palliative treatment of breast cancer. Recent Results Cancer Res 2000;153:61-70. Abstract
Houghton J et al. The ZIPP trial of adjuvant Zoladex in premenopausal patients with early breast cancer: An update at five years. Proc ASCO 2000;Abstract 359.
Jakesz R. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proc ASCO 1999;Abstract 250.
Klijn JG et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 2000;92:903-11. Abstract
Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53. Abstract
Martinetti A et al. The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: Effects on bone metabolism markers. J Steroid Biochem Mol Biol 2000;75:65-73. Abstract
Matsumoto M et al. Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer. Breast Cancer 2000;7(3):237-40. Abstract
Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging 2000;16:261-71. Abstract
Michaud LB et al. Combination endocrine therapy in the management of breast cancer. Oncologist 2001;6(6):538-46. Abstract
Nystedt M et al. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer—Self-rated physiological effects and symptoms. Acta Oncol 2000;39(8):959-68. Abstract
Poikonen P et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer 2000;36(1):43-8. Abstract
Rutqvist LE. Zoladex® and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (C. R. C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G. I. V. I. O). Proc ASCO 1999;Abstract 251.
Sverrisdottir A et al. Bone mineral density in premenopausal patients in a randomized trial of adjuvant endocrine therapy (ZIPP-TRIAL). Proc ASCO 2001;Abstract 96.
capecitabine alone or in combination with taxanes
Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93. Abstract
Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355-63. Abstract
Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71; discussion 72. Abstract
Kusama M et al. A phase II study of XelodaTM (capecitabine) in patients with advanced/metastatic breast carcinoma - The Cooperative Study Group of Capecitabine for Breast Carcinoma. Proc ASCO 2001;Abstract 1924.
Meza LA et al. A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc ASCO 2001;Abstract 2029.
Miles D et al. Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: Analysis of post-study therapy. Breast Cancer Res Treat 2001;Abstract 442.
Procopio G et al. A phase II study of capecitabine in elderly patients with advanced breast cancer. Proc ASCO 2001;Abstract 3134.
Tonkin K et al. Preliminary results of a phase I/II study of weekly docetaxel (Taxotere) combined with intermittent capecitabine (Xeloda) for patients with anthracycline pre-treated metastatic breast cancer. Proc ASCO 2001;Abstract 2016.
Twelves C et al. Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res Treat 2001;Abstract 542.
Venturini M et al. TEX (Taxotere, Epirubicin and Xeloda) regimen as first line chemotherapy in advanced cancer. A multicenter phase II study. Proc ASCO 2001;Abstract 1938.
Venturini M et al. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated, advanced breast cancer patients. Proc ASCO 2000;Abstract 419.
Vukelja SJ et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results. Breast Cancer Res Treat 2001;Abstract 352.
Watanabe T et al. A multicenter phase II trial of XelodaTM (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. Proc ASCO 2001;Abstract 1991.
|
